ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer-Reference-Cited by-同舟云学术

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Published:2017-02-01 Issue:5 Volume:35 Page:599-607
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Crabb Simon J.,Birtle Alison J.,Martin Karen,Downs Nichola,Ratcliffe Ian,Maishman Tom,Ellis Mary,Griffiths Gareth,Thompson Stuart,Ksiazek Lidia,Khoo Vincent,Jones Robert J.

Funder

Cancer Research UK

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-017-0433-4/fulltext.html

Reference23 articles.

1. Cancer Research UK. Cancer Stats: Cancer Statistics for the UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/

2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512. doi: 10.1056/NEJMoa040720

3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513–1520. doi: 10.1056/NEJMoa041318